NCT02771405 2026-04-13
FRI-STC
National Hepatology & Tropical Medicine Research Institute
Phase 3 Completed
Clinical Trials
8 trialsNCT02940496 2025-07-15
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05717400 2024-12-31
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
M.D. Anderson Cancer Center
Phase 4 Terminated
NCT01821963 2020-09-24
Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT02959359 2017-08-07
DAA in the Risk of Recurrence After Curative Treatment of HCC
Taipei Veterans General Hospital, Taiwan
Phase 4 Withdrawn
NCT01559844 2016-07-27
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Gilead Sciences
Phase 2 Completed
NCT00375661 2015-09-02
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
Kyoto University Hospital
Phase 4 Completed
NCT00834860 2010-02-15
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4 Unknown